<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02168439</url>
  </required_header>
  <id_info>
    <org_study_id>PRO13120431</org_study_id>
    <secondary_id>UL1TR000005</secondary_id>
    <nct_id>NCT02168439</nct_id>
  </id_info>
  <brief_title>Intranasal Dexmedetomidine vs Intranasal Midazolam as Anxiolysis Prior to Pediatric Laceration Repair</brief_title>
  <official_title>Double Blinded Randomized Controlled Trial of Intranasal Dexmedetomidine Versus Intranasal Midazolam as Anxiolysis Prior to Pediatric Laceration Repair in the Emergency Department</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this research study is to show superiority of intranasal dexmedetomidine to
      intranasal midazolam as anxiolysis prior to pediatric laceration repairs.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mYPAS Score as Completed by Researchers to Assess Anxiety</measure>
    <time_frame>Day 1</time_frame>
    <description>Primary outcome was the mYPAS scores at the time of positioning for procedure.
mYPAS stands for modified Yale Preoperative anxiety scale. The scale is from minimum 23.3- maximum 100. Higher scores indicate higher anxiety. By prior characterization, scores less than or equal to 30 are classified as not anxious.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mYPAS Scores at Other Time Points</measure>
    <time_frame>Day 1</time_frame>
    <description>mYPAS stands for modified Yale Preoperative anxiety scale. The scale is from minimum 23.3- maximum 100. Higher scores indicate higher anxiety. By prior characterization, scores less than or equal to 30 are classified as not anxious.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS for Anxiety as Completed by Caregiver and Observer</measure>
    <time_frame>Day 1</time_frame>
    <description>VAS, Visual Analog Scale for anxiety. Scale from 0-10 written on a 10 cm horizontal line with the extremes labeled as no anxiety to very anxious.
Vertical line is drawn on the scale at the level of anxiety. The distance was measured.
Higher numbers equal higher anxiety.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Procedure Completion</measure>
    <time_frame>Day 1</time_frame>
    <description>note of whether the procedure was able to be completed</description>
  </other_outcome>
  <other_outcome>
    <measure>Need for Procedural Sedation</measure>
    <time_frame>Day 1</time_frame>
    <description>Whether the patient required procedural sedation for completion of the procedure</description>
  </other_outcome>
  <other_outcome>
    <measure>Anxiolysis Satisfaction</measure>
    <time_frame>Day 1</time_frame>
    <description>Likert scale parent, child life and proceduralist survey
5 point likert scale asking how satisfied the parent or proceduralist is with the anxiolysis from the medication.
1 being not satisfied at all, 3 neutral, 5 very satisfied.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Laceration</condition>
  <condition>Anxiety</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intranasal Dexmedetomidine 2 micrograms/kilogram once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Midazolam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intranasal Midazolam 0.4 milligram/kilogram</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <arm_group_label>Midazolam</arm_group_label>
    <other_name>Versed</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presenting to Children's Hospital of Pittsburgh of University of Pittsburgh Medical
             Center

          -  Laceration &lt;5 cm in total length

          -  Require simple suture laceration repair

        Exclusion Criteria:

          -  Allergies/intolerance/contraindication to the study drugs

          -  Lacerations requiring complex (multilayer) repair or total laceration length&gt;5cm
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Desiree Neville, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2014</study_first_submitted>
  <study_first_submitted_qc>June 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2014</study_first_posted>
  <results_first_submitted>September 19, 2016</results_first_submitted>
  <results_first_submitted_qc>January 20, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 10, 2017</results_first_posted>
  <last_update_submitted>January 20, 2017</last_update_submitted>
  <last_update_submitted_qc>January 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Desiree Neville, MD</investigator_full_name>
    <investigator_title>M.D., Pediatric Emergency Medicine Fellow Physician</investigator_title>
  </responsible_party>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Midazolam</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lacerations</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dexmedetomidine</title>
          <description>Intranasal Dexmedetomidine 2 micrograms/kilogram once
Dexmedetomidine: 20 patients enrolled, 20 underwent analysis</description>
        </group>
        <group group_id="P2">
          <title>Midazolam</title>
          <description>Intranasal Midazolam 0.4 milligram/kilogram
Midazolam: 20 patients enrolled, 18 underwent analysis</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>38 patients were analyzed in total.</population>
      <group_list>
        <group group_id="B1">
          <title>Dexmedetomidine</title>
          <description>Intranasal Dexmedetomidine 2 micrograms/kilogram once
Dexmedetomidine: .</description>
        </group>
        <group group_id="B2">
          <title>Midazolam</title>
          <description>Intranasal Midazolam 0.4 milligram/kilogram
Midazolam: .</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.44" lower_limit="1.6" upper_limit="5.4"/>
                    <measurement group_id="B2" value="3.15" lower_limit="1.0" upper_limit="5.4"/>
                    <measurement group_id="B3" value="3.21" lower_limit="1.0" upper_limit="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Laceration length</title>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.59" spread=".87"/>
                    <measurement group_id="B2" value="1.44" spread=".73"/>
                    <measurement group_id="B3" value="1.52" spread=".79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>mYPAS Score as Completed by Researchers to Assess Anxiety</title>
        <description>Primary outcome was the mYPAS scores at the time of positioning for procedure.
mYPAS stands for modified Yale Preoperative anxiety scale. The scale is from minimum 23.3- maximum 100. Higher scores indicate higher anxiety. By prior characterization, scores less than or equal to 30 are classified as not anxious.</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine</title>
            <description>Intranasal Dexmedetomidine 2 micrograms/kilogram once
Dexmedetomidine: 20 patients enrolled, 20 underwent analysis</description>
          </group>
          <group group_id="O2">
            <title>Midazolam</title>
            <description>Intranasal Midazolam 0.4 milligram/kilogram
Midazolam: 20 patients enrolled, 18 underwent analysis</description>
          </group>
        </group_list>
        <measure>
          <title>mYPAS Score as Completed by Researchers to Assess Anxiety</title>
          <description>Primary outcome was the mYPAS scores at the time of positioning for procedure.
mYPAS stands for modified Yale Preoperative anxiety scale. The scale is from minimum 23.3- maximum 100. Higher scores indicate higher anxiety. By prior characterization, scores less than or equal to 30 are classified as not anxious.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3" lower_limit="23.3" upper_limit="30.8"/>
                    <measurement group_id="O2" value="36.3" lower_limit="32.5" upper_limit="38.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>mYPAS Scores at Other Time Points</title>
        <description>mYPAS stands for modified Yale Preoperative anxiety scale. The scale is from minimum 23.3- maximum 100. Higher scores indicate higher anxiety. By prior characterization, scores less than or equal to 30 are classified as not anxious.</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine</title>
            <description>Intranasal Dexmedetomidine 2 micrograms/kilogram once
Dexmedetomidine: 20 patients enrolled, 20 underwent analysis</description>
          </group>
          <group group_id="O2">
            <title>Midazolam</title>
            <description>Intranasal Midazolam 0.4 milligram/kilogram
Midazolam: 20 patients enrolled, 18 underwent analysis</description>
          </group>
        </group_list>
        <measure>
          <title>mYPAS Scores at Other Time Points</title>
          <description>mYPAS stands for modified Yale Preoperative anxiety scale. The scale is from minimum 23.3- maximum 100. Higher scores indicate higher anxiety. By prior characterization, scores less than or equal to 30 are classified as not anxious.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Anxiety</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.8" lower_limit="36.7" upper_limit="82.5"/>
                    <measurement group_id="O2" value="47.1" lower_limit="40.0" upper_limit="51.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety at Wound Washout</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.5" lower_limit="23.3" upper_limit="88.3"/>
                    <measurement group_id="O2" value="47.1" lower_limit="34.2" upper_limit="67.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety at First Stitch Placement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3" lower_limit="23.3" upper_limit="89.2"/>
                    <measurement group_id="O2" value="35.4" lower_limit="31.3" upper_limit="52.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VAS for Anxiety as Completed by Caregiver and Observer</title>
        <description>VAS, Visual Analog Scale for anxiety. Scale from 0-10 written on a 10 cm horizontal line with the extremes labeled as no anxiety to very anxious.
Vertical line is drawn on the scale at the level of anxiety. The distance was measured.
Higher numbers equal higher anxiety.</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine</title>
            <description>Intranasal Dexmedetomidine 2 micrograms/kilogram once
Dexmedetomidine: 20 patients enrolled, 20 underwent analysis</description>
          </group>
          <group group_id="O2">
            <title>Midazolam</title>
            <description>Intranasal Midazolam 0.4 milligram/kilogram
Midazolam: 20 patients enrolled, 18 underwent analysis</description>
          </group>
        </group_list>
        <measure>
          <title>VAS for Anxiety as Completed by Caregiver and Observer</title>
          <description>VAS, Visual Analog Scale for anxiety. Scale from 0-10 written on a 10 cm horizontal line with the extremes labeled as no anxiety to very anxious.
Vertical line is drawn on the scale at the level of anxiety. The distance was measured.
Higher numbers equal higher anxiety.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VAS Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="2.9"/>
                    <measurement group_id="O2" value="3.5" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS Position</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="2.9"/>
                    <measurement group_id="O2" value="1.6" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS Recovery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".7" spread="1.6"/>
                    <measurement group_id="O2" value="1.2" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Procedure Completion</title>
        <description>note of whether the procedure was able to be completed</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine</title>
            <description>Intranasal Dexmedetomidine 2 micrograms/kilogram once
Dexmedetomidine: 20 patients enrolled, 20 underwent analysis</description>
          </group>
          <group group_id="O2">
            <title>Midazolam</title>
            <description>Intranasal Midazolam 0.4 milligram/kilogram
Midazolam: 20 patients enrolled, 18 underwent analysis</description>
          </group>
        </group_list>
        <measure>
          <title>Procedure Completion</title>
          <description>note of whether the procedure was able to be completed</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Need for Procedural Sedation</title>
        <description>Whether the patient required procedural sedation for completion of the procedure</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine</title>
            <description>Intranasal Dexmedetomidine 2 micrograms/kilogram once
Dexmedetomidine: 20 patients enrolled, 20 underwent analysis</description>
          </group>
          <group group_id="O2">
            <title>Midazolam</title>
            <description>Intranasal Midazolam 0.4 milligram/kilogram
Midazolam: 20 patients enrolled, 18 underwent analysis</description>
          </group>
        </group_list>
        <measure>
          <title>Need for Procedural Sedation</title>
          <description>Whether the patient required procedural sedation for completion of the procedure</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Anxiolysis Satisfaction</title>
        <description>Likert scale parent, child life and proceduralist survey
5 point likert scale asking how satisfied the parent or proceduralist is with the anxiolysis from the medication.
1 being not satisfied at all, 3 neutral, 5 very satisfied.</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine</title>
            <description>Intranasal Dexmedetomidine 2 micrograms/kilogram once
Dexmedetomidine: 20 patients enrolled, 20 underwent analysis</description>
          </group>
          <group group_id="O2">
            <title>Midazolam</title>
            <description>Intranasal Midazolam 0.4 milligram/kilogram
Midazolam: 20 patients enrolled, 18 underwent analysis</description>
          </group>
        </group_list>
        <measure>
          <title>Anxiolysis Satisfaction</title>
          <description>Likert scale parent, child life and proceduralist survey
5 point likert scale asking how satisfied the parent or proceduralist is with the anxiolysis from the medication.
1 being not satisfied at all, 3 neutral, 5 very satisfied.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Parent Satisfaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" spread="1.3"/>
                    <measurement group_id="O2" value="5" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proceduralist Satisfaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="1.3"/>
                    <measurement group_id="O2" value="5" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Dexmedetomidine</title>
          <description>Intranasal Dexmedetomidine 2 micrograms/kilogram once
Dexmedetomidine: 20 patients enrolled, 20 underwent analysis</description>
        </group>
        <group group_id="E2">
          <title>Midazolam</title>
          <description>Intranasal Midazolam 0.4 milligram/kilogram
Midazolam: 20 patients enrolled, 18 underwent analysis</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>fall</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>vomiting</sub_title>
                <description>vomiting after going home from repair</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>fall</sub_title>
                <description>fall after repair while in the ED</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>2 patients not included in the midazolam group: one for equipment malfunction leading to no data collected and the second due to weight error resulting in the patient receiving over twice the dose. Both recognized around the time of enrollment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Desiree Neville</name_or_title>
      <organization>Children's Hospital of Pittsburgh of UPMC</organization>
      <phone>4126927692</phone>
      <email>desiree.neville@chp.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

